Treatment-related adverse events of grade 3 or 4 occurred in 19 (40.4%) patients, comprising neutropenia (n = 9, 19.1%), AST level elevation (n = 7, 14.9%), alanine aminotransferase (ALT) level elevation (n = 5, 10.6%), and thrombocytopenia (n = 4, 8.5%). The gene discussed is GPT; the disease is neutropenia.